Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gossamer Bio Inc GOSS

Healthcare Biotechnology
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor... see more

Recent & Breaking News (NDAQ:GOSS)

Gossamer Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Gossamer Bio, Inc. To Contact The Firm

Newsfile May 18, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS

GlobeNewswire May 17, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS

ACCESSWIRE IA May 15, 2020

GOSS & ZM INVESTOR NOTIFICATION: Bronstein, Gewirtz & Grossman LLC Updates Investors of Class Actions and Encourages Investors to Contact the Firm

GlobeNewswire May 13, 2020

FAST-APPROACHING DEADLINE: Block & Leviton Filed the First Lawsuit Against Gossamer Bio, Inc. for Securities Fraud; Shareholders Who Have Lost Money Should Contact the Firm

GlobeNewswire May 13, 2020

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA May 12, 2020

Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924)

GlobeNewswire May 12, 2020

Gossamer Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update

Business Wire May 12, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS

ACCESSWIRE IA May 12, 2020

SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA May 11, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS

GlobeNewswire May 10, 2020

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA May 8, 2020

Gossamer Bio to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 12, 2020

Business Wire May 8, 2020

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA May 7, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS

ACCESSWIRE IA May 7, 2020

GOSSAMER DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Gossamer Bio, Inc. To Contact The Firm

ACCESSWIRE IA May 6, 2020

SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA May 5, 2020

GOSS SHAREHOLDER UPDATE: Bronstein, Gewirtz & Grossman, LLC Reminds Gossamer Bio, Inc. Investors of Class Action and Encourages Investors to Contact the Firm

ACCESSWIRE IA May 5, 2020

Lawsuit for Investors in Gossamer Bio, Inc. (NASDAQ: GOSS) Shares Announced by Shareholders Foundation

ACCESSWIRE IA May 5, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS

ACCESSWIRE IA May 4, 2020